Is Schizophrenia Treatable?
Schizophrenia
includes a range of mental health complications associated with cognitive
impairment, disorganized behavior, speech difficulty, hallucinations, and
delusions (Patel, Cherian, Gohil, & Atkinson, 2014). The chronicity of
schizophrenia leads to negative symptoms that potentially impact executive
function, working memory, and attention span of the affected patients. However,
the positive symptoms of schizophrenia include hallucinations, delusions, and
suspiciousness. The schizophrenia’s inherent heterogeneity pattern is the
preliminary cause of differences in opinions regarding its pathophysiology,
etiology, and diagnostic parameters. Schizophrenia patients commonly experience
the following problems in their day-to-day life. However, these problems
variably impact men and women of various age groups (Seeman, 2018).
- The schizophrenia patients
usually deny their symptoms while resisting to correlate them with their
illness.
- Every stimulus leads to the
development of a perception that induces hallucinations or delusions in
schizophrenia patients.
- The schizophrenia
hallucinations predominantly impact the vision, taste, smell, or touch
perceptions of the affected patients.
- Most of the schizophrenia
patients experience auditory hallucinations that potentially interfere in
their daily activities.
- Schizophrenia-based
delusions potentially deteriorate the beliefs and perceptions of the
affected patients to an unprecedented level.
- The personal themes of
delusions are based on the feelings of persecution and passivity. The
schizophrenia patients consider themselves as the victims of a stratagem
and threatening circumstances.
- The passive thoughts of the
schizophrenia patients force them to believe in the existence of an
external force that potentially threatens their survival and
well-being.
- Schizophrenia patients
usually experience religious, sexual, or grandiose delusions.
- The schizophrenia patients’
irrational thinking pattern reflects through their illogical decisions and
speech complications.
- The schizophrenia patients
abruptly deflect their categorical chain of thoughts and fail to use
language coherently.
- Some of the passive behavioral manifestations of schizophrenia include paucity of speech, emotional blunting, loss of initiative/motivation, self-neglect, and social withdrawal.
What are the Commonly Reported subdivisions of
Schizophrenia?
Schizophrenia is divided into the following subtypes (Picchioni &
Murray, 2007).
- The paranoid schizophrenia manifests through prominent hallucinations or delusions.
- The hebephrenic schizophrenia manifests through incongruous/sustained flattened affect, irrational behavior, and disturbing thoughts.
- Catatonic schizophrenia leads to the development of rigid behavior. The patients also experience behavioral conflicts based on posturing, excitement, and stupor.
- The simple schizophrenia manifests through the progressive intensification of passive symptoms, absence of personal drive, and cognitive decline. The patients usually reflect a marked reduction in their employment/academic performance and social functioning.
What are the Commonly Reported Causes of
Schizophrenia?
The following attributes
predominantly elevate the risk of schizophrenia in predisposed patients (IOM,
2001). However, the pathomechanism of schizophrenia is still not clearly
understood until the date (Stępnicki, Kondej, & Kaczor, 2018).
- Reduced self-care
- Inappropriate nutrition
- Heavy smoking
- Medical negligence
- Childbirth/pregnancy complications
- Prolonged consumption of psychotropic or psychoactive drugs
- Family history of mental illnesses
- Genetic predisposition
What are the Complications Faced by Schizophrenia
Patients?
The adverse psychosocial
outcomes of schizophrenia potentially increase the risk of the following
conditions (Mayo Clinic, 2020).
- Aggressive or violent behavior
- Medical comorbidities
- Social isolation
- Homelessness and financial issues
- Unemployment
- Nicotine/drug addiction and alcoholism
- Depression
- Anxiety
- Obsessive-compulsive disorder
- Suicidal ideation
What is the Pathophysiology of Schizophrenia?
Schizophrenia drastically impacts the neuropsychological performance of
the affected patients (Tamminga, 2000). The chronic institutionalization and
early onset of the psychotic symptoms potentially impact the patients’ coping
skills and performance levels. The schizophrenia patients exhibit reduced
performance outcomes based on their deteriorated pattern recognition skills,
verbal fluency, attention, memory, and intelligence. They also develop serious
language/memory/attention deficits that predominantly impact their contextual
information processing abilities. The disruption in cognitive circuitry and
cerebral function of the schizophrenia patients impacts their thinking pattern,
learning skills, and perceptions. Sensory stimuli in schizophrenia patients impact
their eye movements and also lead to deflection in their FRG
(electroencephalography) outcomes (Tamminga, 2000). The abnormal smooth pursuit
eye movements of schizophrenia patients have an unknown etiology. However, they
might have an active genetic cause within their genome. The motion processing
problem of schizophrenia patients relates to their sustained cerebral defects.
They experience considerable difficulty in linking the movements of their eyes
with motion information. They also lack the short-term memory for retaining the
motion information (Tamminga, 2000). The abnormal eye movements of the
schizophrenia patients also reveal questionable defects in their middle frontal
and/or parietal cortices. Some of the schizophrenia patients exhibit saccadic
eye movements apart from experiencing smooth pursuit movements. The evoked
potentials based on cognitive or sensory episodes lead to signal-averaged
abnormal EEG alterations in schizophrenia patients. These alterations
predominantly occupy P50 and P300 locations of EEG (Tamminga, 2000).
The schizophrenia patients variably reflect structural and functional
changes in their brains that effectively correlate with their clinical symptoms
(Tamminga, 2000). For example, A marked reduction in the volume of the temporal
gyrus in schizophrenia patients is a well-defined clinical attribute.
Similarly, schizophrenia manifests through a sustained reduction in the volumes
of hippocampal, entorhinal, and parahippocampal cortices of the middle temporal
cortex. The schizophrenia patients also exhibit a considerable reduction in the
vascular supply of their prefrontal cortex. Furthermore, they also encounter
metabolic alterations and blood supply reduction in the middle frontal gyrus
and anterior cingulate of their frontal cortex. A marked decrease in regional
cerebral blood flow predominantly leads to the development of psychosocial
manifestations in schizophrenia patients (Tamminga, 2000). These outcomes
reveal potential CNS (central nervous system) abnormalities in the
schizophrenia patients that lead to the development of their negative symptoms.
The fMRI (functional magnetic resonance imagining) reveals a contradictory
finding based on regional cerebral blood flow elevation in some of the
schizophrenia patients. This variable finding warrants prospective analysis to
understand the causative mechanisms associated with schizophrenia phase
contributions and performance demands in the affected patients (Tamminga,
2000). The regional cerebral blood flow differences in schizophrenia patients
necessitate a comparative clinical assessment of their inferior and middle
frontal cortices to understand their contribution to the clinical
manifestations.
Evidence-based clinical literature reveals functional variations in the
hippocampus of schizophrenia patients (Tamminga, 2000). Some of the
schizophrenia patients do not exhibit any structural or functional hippocampal
alteration despite marked variations in their regional cerebral blood flow
patterns (rCBF). Contrarily, some of the schizophrenia patients exhibit a
considerable reduction in their hippocampus rCBF under the influence of
ketamine, which is a non-competitive JV-methyl-D-aspartate (NM'DA) antagonist.
Scientists provide several other theories related to the pathophysiology and
causative mechanisms of schizophrenia (Tamminga, 2000). Some of them advocate
the impact of an overactive dopaminergic system on the psychosocial
manifestations of schizophrenia patients. Some of the researchers still believe
in the hypothesis that advocates the molecular docking mechanism dominating the
interaction between the brain’s dopamine receptors and antipsychotic drugs in
schizophrenia patients. This interaction presumably minimizes schizophrenia’s
psychotic manifestations (Tamminga, 2000).
Some of the research studies reveal sustained defects in the long-tract
mechanisms dominating the interactions between subcortical regions and the
frontal cortex in schizophrenia patients (Tamminga, 2000). These defects
potentially impact the functionality of thalamus and basal ganglia that
eventually increases the intensity of functional and cognitive abnormalities.
The modulation of the frontal cortical function in schizophrenia patients could
occur under the influence of functional alterations in neuromodulators,
neurotransmitters, and their innervations. Furthermore, thalamic dysfunction in
schizophrenia patients could also induce functional alterations in their
frontal cortex. The neurodevelopmental factors of schizophrenia correlate with
the genetic predisposition of the high-risk populations (Tamminga, 2000). This
indicates that schizophrenia’s pathobiology is already programmed since birth
and intensifies with age under the influence of environmental factors. The
premorbid cognitive predictors and their interactions with prenatal or
perinatal episodes in many scenarios explain the development of psychotic
manifestations in schizophrenia patients. The dysfunction of the neural
apparatus of the schizophrenia patients, however, reflects during the late teenage.
Interestingly, not all schizophrenia patients could experience
neurodevelopmental changes despite the existence of similar pathophysiology
(Tamminga, 2000). The etiological variations in schizophrenia patients require
clinical investigation in the context of developing novel treatment approaches
for mitigating the psychotic episodes. Research studies also reveal the limbic
system disruptions in schizophrenia patients. The postmortem examinations of
some of the schizophrenia patients reveal the elevated expression of TRG genes
under the impact of phencyclidine. The expression of these genes reveals the
neuronal responses recorded after the administration of phencyclidine. Some of
the studies reveal a marked elevation in the NMDA-sensitive glutamate receptor’s
NR subunit under the influence of phencyclidine. The NR elevation typically
occurs in the hippocampus of schizophrenia patients. Furthermore, the failure
of the GABA-ergic (inhibitory gamma-aminobutyric acid) system’s glutamatergic
excitation leads to the feed-forward inhibition in schizophrenia patients
(Tamminga, 2000). This eventually elevates resting regional cerebral blood flow
inside the hippocampus of the schizophrenia patients. However, researchers
still require conducting extensive studies to evaluate the inconclusive
pathophysiological evidence in the context of schizophrenia.
What are the Unmet Clinical Demands and Treatment
Options for Schizophrenia Management?
The clinicians require customizing therapeutic interventions for schizophrenia
patients while considering the following therapeutic options/targets (Fellner,
2017).
- Evidence-based strategies for enhancing pharmacotherapeutic compliance
- Meaningful utilization of safe and effective drugs
- Selection of novel and approved treatment methods for the health care management of treatment-resistant individuals
- Mitigation of negative symptoms including social withdrawal, apathy, and lethargy
- Cognitive enhancement through pharmacotherapy
- The utilization of 1st and 2nd generation antipsychotics
- The typical or 1st generation antipsychotics include haloperidol, fluphenazine, and chlorpromazine
- The 2nd generation antipsychotics include risperidone, olanzapine, and clozapine
- The 2nd generation antipsychotics assist in controlling the positive symptoms of schizophrenia
- The 2nd generation antipsychotics associate with fewer side-effects including sedative complications, cardiovascular disease, and movement disorders
- Multivitamin therapy based on vitamins B12, B6, E, and C in addition to the baseline drug therapy helps in reducing schizophrenia manifestations
- The 1st generation antipsychotics elevate the risk of the following conditions
- Weight gain
- Type 2 diabetes mellitus
- Sexual dysfunction
- Seizures
- Sedation
- QT interval prolongation
- Postural hypotension
- Neuroleptic malignant syndrome
- Hyperprolactinemia
- Extrapyramidal symptoms
- Dyslipidemia
- Anticholinergic effects
What are the Nonpharmacological Schizophrenia
Management Options?
The clinicians recommend the use of integrative management approaches based on pharmacotherapeutic and non-pharmacological interventions for controlling the negative and positive symptoms of schizophrenia. Some of these interventions are listed below (Ganguly, Soliman, & Moustafa, 2018) (Matei, Mihailescu, & Davidson, 2014).
- The administration of CBT (cognitive behavioral therapy) along with conservative management helps in mitigating delusions, hallucinations, suicidal ideation, sedentary, and aggression of the schizophrenia patients.
- CBT potentially helps in improving the health-related behavior, feelings, and thinking pattern of the schizophrenia patients
- CBT focusses on mitigating the social impairments of the schizophrenia patients
- The cognitive restructuring technique challenges the patients to falsify their illusions and irrational beliefs
- CBT-based enhancement of conversational skills assists the schizophrenia patients to improve their interpersonal relations with family members
- CBT also assists in controlling the disorganized behavior of the schizophrenia patients
- Dietary management with increased consumption of vitamin D and folic acid helps in minimizing the negative symptoms of schizophrenia.
- The positive modifications in the home environment and compassionate or empathetic dealing by family members also help in controlling schizophrenia complications to a measurable extent
What are the Recommended Diagnostic Measures and
Evaluation Strategies for Schizophrenia Patients?
The following comprehensive
interventions assist in evaluating the causes, treatment response, and
prognostic outcomes of schizophrenia symptoms (Grover, Chakrabarti, Kulhara,
& Avasthi, 2017).
- Neuroimaging for the assessment of treatment response, neurological signs, and psychotic episodes
- Mental status examination
- Comprehensive psychological assessment of executive functions
- The utilization of standardized rating scales for evaluating the entire facets of schizophrenia manifestations
- Comprehensive assessment of medication accessibility, family care paradigm, environmental issues, and treatment compliance/side-effects
- The assessment of the family members’ beliefs, perceptions, attitudes, knowledge, and awareness of schizophrenia symptoms
- Basic clinical investigations including electrocardiogram, renal function test, liver function test, lipid profile, Blood glucose level, HbA1C, and hemogram
- Assessment of sociocultural milieu
- Assessment of psychosocial and physical functioning levels
- Evaluation of the risk of suicidal tendency and self-harm
- Assessment of substance abuse pattern, psychiatric complications, physical comorbidities, cognitive manifestations, and symptom dimensions/severity
- Physical examination based on waist circumference, body mass index, and vital signs
- Complete clinical history, including medication use patterns and family history
- A comprehensive evaluation of caregivers and patients
References
Chein, W. T., & Yip,
A. L. (2013). Current approaches to treatments for schizophrenia spectrum
disorders, part I: an overview and medical treatments. Neuropsychiatric
Disease and Treatment, 1311-1332. doi:10.2147/NDT.S37485
Fellner, C. (2017). New
Schizophrenia Treatments Address Unmet Clinical Needs. Pharmacy and
Therapeutics , 42(2), 130–134. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265239/
Ganguly, P., Soliman, A.,
& Moustafa , A. A. (2018). Holistic Management of Schizophrenia Symptoms
Using Pharmacological and Non-pharmacological Treatment. Frontiers in Public
Health, 6(166). doi:10.3389/fpubh.2018.00166
Grover, S., Chakrabarti,
S., Kulhara , P., & Avasthi, A. (2017). Clinical Practice Guidelines for
Management of Schizophrenia. Indian Journal of Psychiatry, 59(1), S19-S33.
doi:10.4103/0019-5545.196972
IOM. (2001).
Schizophrenia. In Neurological, Psychiatric, and Developmental Disorders:
Meeting the Challenge in the Developing World. Washington (DC): National
Academies Press (US). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK223456/
Matei, V. P., Mihailescu ,
A. I., & Davidson , M. (2014). Is non-pharmacological treatment an option
for certain schizophrenia patients? Psychiatria Danubina, 26(4),
308-313. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25377364
Mayo Clinic. (2020). Schizophrenia.
Retrieved from
https://www.mayoclinic.org/diseases-conditions/schizophrenia/symptoms-causes/syc-20354443
Muench, J., & Hamer ,
A. M. (2010). Adverse Effects of Antipsychotic Medications. American Family
Physician, 81(5), 617-622. Retrieved from
https://www.aafp.org/afp/2010/0301/p617.html
Patel, K. R., Cherian, J.,
Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment
Options. Pharmacy and Therapeutics, 39(9), 638-645. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159061/
Picchioni, M. M., &
Murray, R. M. (2007). Schizophrenia. BMJ, 335(7610), 91-95.
doi:10.1136/bmj.39227.616447.BE
Seeman, M. V. (2018).
Women who suffer from schizophrenia: Critical issues. World Journal of
Psychiatry, 8(5), 125-136. doi:10.5498/wjp.v8.i5.125
Stępnicki, P., Kondej, M.,
& Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. Molecules.
doi:10.3390/molecules23082087
Tamminga, C. A., & Medoff, D. R. (2000). The biology of schizophrenia. Dialogues in Clinical Neuroscience, 2(4), 339-348. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181617/